Physician profile
Jerry L Smith
NPI 1811957384
$739.50
in general payments reported to CMS, 2019-2025
16 companies · $40.96 in 2025
The $40.96 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $224 · 2021: $12.67 · 2022: $18.40 · 2023: $138 · 2024: $116 · 2025: $40.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $294.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $215.51 | 2023-2024 | Ubrelvy, Botox, Qulipta |
| Allergan, INC. | $174.35 | 2019-2022 | |
| Amgen INC. | $63.97 | 2019-2020 | |
| Saluda Medical Americas, INC. | $40.96 | 2025 | Evoke |
| Tersera Therapeutics LLC | $35.34 | 2019 | |
| Grt US Holding, INC. | $32.51 | 2020-2021 | |
| Merz North America, INC. | $29.70 | 2020 | |
| Pfizer INC. | $22.49 | 2019 | |
| Abbott Laboratories | $20.83 | 2023 | Proclaim |
| Ge Healthcare | $17.84 | 2020 | |
| Almatica Pharma LLC | $17.40 | 2024 | Teriparatide |
| Assertio Therapeutics, INC. | $16.57 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.43 | 2019 | |
| Medtronic USA, INC. | $12.59 | 2019 | |
| Redhill Biopharma INC. | $12.04 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.